41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Baroni, Matteo Libero, Sanchez Martinez, Diego, Gutierrez Aguera, Francisco, Roca Ho, Heleia, Castella, Maria, Zanetti, Samanta Romina, Velasco Hernandez, Talia, Diaz de la Guardia, Rafael, Castaño, Julio, Anguita, Eduardo, Vives, Susana, Nomdedeu, Josep, Lapillone, Helene, Bras, Anne E, van der Velden, Vincent H J, Junca, Jordi, Marin, Pedro, Bataller, Alex, Esteve, Jordi, Vick, Binje, Jeremias, Irmela, Lopez, Angel, Sorigue, Marc, Bueno, Clara, Menendez, Pablo
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292050/
https://ncbi.nlm.nih.gov/pubmed/32527933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000845
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados